Form 4: Stoke Therapeutics' Chief Medical Officer Executes Stock Option and Sells Shares

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 3, 2024, Barry Ticho, the Chief Medical Officer of Stoke Therapeutics, exercised stock options to acquire 10,000 shares of common stock at a price of $0.60 per share.
• He then sold 9,400 shares at a weighted average price of $14.9187, with individual sales ranging from $14.35 to $15.34 per share.
• Additionally, he sold 600 shares at a weighted average price of $15.4083, with individual sales ranging from $15.35 to $15.47 per share.
• Following these transactions, Ticho directly owns 2,485 shares of common stock and holds options for 30,000 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions were pre-planned under a 10b5-1 trading plan. It's a routine disclosure of stock transactions by a company executive.

Industry Context

Executive stock transactions are common and closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. Sales under a 10b5-1 plan are less indicative of immediate sentiment as they are pre-planned.

Stakeholder Impact

• The stock sales may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small volume of shares sold.

Key Dates